| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.086 | 0.02 |
| mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | -0.083 | 0.02 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.076 | 0.02 |
| mRNA | embelin | GDSC1000 | pan-cancer | AAC | -0.079 | 0.03 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.11 | 0.03 |
| mRNA | AZD6482 | GDSC1000 | pan-cancer | AAC | -0.072 | 0.03 |
| mRNA | JQ-1:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.075 | 0.03 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.03 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | -0.075 | 0.03 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.12 | 0.03 |